论文部分内容阅读
目的观察孟鲁司特钠联合小剂量吸入型糖皮质激素对小儿哮喘的治疗效果。方法选取医院2015年6月-2016年1月收治的哮喘患儿86例,随机分为对照组和试验组各43例。对照组应用孟鲁司特钠小剂量布地奈德治疗,试验组应用孟鲁司特钠联合小剂量布地奈德治疗;比较2组治疗效果。结果试验组症状缓解时间明显短于对照组,差异有统计学意义(P<0.05)。试验组第1秒用力肺活量(FEV1)及呼气峰流量(PEF)均显著优于对照组,差异有统计学意义(P<0.05);试验组总有效率达97.67%明显高于对照组的86.05%,差异有统计学意义(P<0.05)。试验组、对照组不良反应发生率分别为4.65%、6.98%,差异无统计学意义(P>0.05)。结论联合应用孟鲁司特钠及小剂量吸入型糖皮质激素治疗小儿哮喘具有起效快、疗效好、安全性高等优点。
Objective To observe the therapeutic effect of montelukate combined with low-dose inhaled glucocorticoid on pediatric asthma. Methods Totally 86 children with asthma admitted to the hospital from June 2015 to January 2016 were randomly divided into control group and experimental group, 43 cases each. Control group, montelukast sodium low-dose budesonide treatment, the experimental group with montelukast sodium combined with low-dose budesonide treatment; the treatment effect of two groups were compared. Results The symptom relief time of the experimental group was significantly shorter than that of the control group, the difference was statistically significant (P <0.05). The forced expiratory volume (FEV1) and peak expiratory flow (PEF) in the experimental group were significantly better than those in the control group (P <0.05). The total effective rate in the experimental group was 97.67%, which was significantly higher than that in the control group 86.05%, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group and control group were 4.65% and 6.98%, respectively, with no significant difference (P> 0.05). Conclusion Combined use of montelukast sodium and low-dose inhaled glucocorticoid treatment of pediatric asthma with rapid onset, good efficacy, high safety and so on.